Sol-Gel Technologies Ltd. SLGL

Sol-Gel Technologies completes last patient last visit in pivotal Phase 3 trial of SGT-610 for Gorlin Syndrome. Phase 3 milestone advances SGT-610 toward data readout and possible approval, materially lifting company prospects.

Sol-Gel Technologies Ltd. (SLGL) may find a bottom soon as a hammer chart pattern is formed, with rising optimism among Wall Street analysts about future earnings. The article highlights significant potential impact on SLGL's future and market performance due to positive earnings estimate revisions and Zacks Rank #1.

Sol-Gel Technologies Ltd. reported second quarter 2026 financial results and provided corporate updates. Quarterly financial results and updates affect perceptions of financial performance and near-term valuation.

Sol-Gel Technologies Ltd. (SLGL) posted a Q1 loss and missed revenue estimates. Quarterly loss and revenue shortfall signal near-term pressure on valuation and sentiment.

Sol-Gel Technologies Ltd. reported first quarter 2026 financial results and provided corporate updates. Quarterly results and updates can shift near-term market views on performance without guaranteed long-term trajectory change.

Sol-Gel Technologies Ltd. announced the pricing of its oversubscribed underwritten offering, signaling strong investor demand and successful capital raise. Oversubscribed offering delivers critical funding to support operations and development, significantly enhancing financial flexibility and market sentiment.

Sol-Gel Technologies Ltd. (SLGL) reported a fourth-quarter loss and missed revenue estimates. Q4 loss and missed revenue estimates highlight financial underperformance, moderately affecting short-term market sentiment and stock performance.

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) has seen its shareholders achieve a remarkable 940% return over the past year, reflecting significant growth and investor confidence in the company's performance and prospects. The substantial return indicates a significant impact on investor sentiment and the company's market trajectory.

Sol-Gel Technologies Ltd. is positioned to drive business growth due to its strong financial health and strategic initiatives. The company has demonstrated the ability to invest in product development and expand its market presence, which could lead to increased revenue and shareholder value. Analysts believe that Sol-Gel's focus on innovation and market expansion will support its growth trajectory in the coming years. Strong financial health and strategic initiatives are likely to significantly impact future performance and investor sentiment.

Sol-Gel Technologies Ltd. announced the unblinding of its Phase 1b study for SGT-210, a treatment for Darier Disease. The study's results indicate that SGT-210 is well-tolerated and shows promising efficacy, with a significant percentage of patients achieving a clinical response. The company plans to advance SGT-210 into Phase 2 trials, aiming to further evaluate its safety and effectiveness. This update marks a critical step in the development of SGT-210, which targets a rare genetic skin disorder. The advancement of SGT-210 into Phase 2 trials represents a significant strategic move that could enhance the company's product pipeline and market position.

Sol-Gel Technologies Ltd. (SLGL) has been upgraded to a Zacks Rank #2 (Buy) due to positive earnings outlook and rising earnings estimates. The article highlights a significant impact on Sol-Gel Technologies' future and market performance through improved earnings outlook and rising earnings estimates.

Sol-Gel Technologies Ltd. (SLGL) reported its financial results for the third quarter of 2025, highlighting key metrics and corporate updates. The company showcased progress in its product pipeline and strategic initiatives aimed at enhancing market presence. Financial performance indicators reflected ongoing efforts to improve operational efficiency and drive growth. Management provided insights into future plans and expectations, signaling a commitment to innovation and market expansion. Financial results and corporate updates indicate moderate influence on the company's performance and market positioning.

Insiders at Sol-Gel Technologies Ltd. have made significant stock purchases totaling US$867.1k, indicating confidence in the company's future performance. This buying activity suggests that those with inside knowledge believe the stock is undervalued or that positive developments are on the horizon. Such insider transactions often serve as a signal to investors about the company's prospects. Insider buying can indicate confidence in the company's future, potentially influencing market sentiment and stock performance.

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) has seen its shareholders achieve a remarkable 240% return over the past year, reflecting significant growth and investor confidence in the company's performance and prospects. The substantial return indicates a significant positive shift in market sentiment and potential for future growth.

Sol-Gel Technologies Ltd. announced that Health Canada has approved EPSOLAY®, a novel topical treatment for rosacea. This approval marks a significant milestone for the company, as EPSOLAY® is designed to provide effective relief for patients suffering from this skin condition. The product is expected to enhance Sol-Gel's portfolio and strengthen its market position in dermatological therapies. Health Canada approval of EPSOLAY® is a significant regulatory milestone that could enhance market presence and financial performance.

Sol-Gel Technologies Ltd. (SLGL) reported its financial results for the second quarter of 2025, highlighting key metrics and corporate updates. The company continues to focus on its product pipeline and strategic initiatives aimed at enhancing growth and market presence. Management provided insights into operational developments and future outlook, emphasizing ongoing efforts to drive innovation and improve financial performance. The financial results and corporate updates indicate moderate influence on the company's performance and market positioning.

Sol-Gel Technologies Ltd. is facing scrutiny over its cash burn rate as it continues to operate without generating significant revenue. The company has been investing heavily in research and development, which has led to increased expenses. Investors are concerned about the sustainability of its financial position and the potential need for additional funding in the near future. Analysts are closely monitoring the situation to assess the impact on the company's future performance and market standing. The cash burn rate raises concerns about financial sustainability, which could moderately influence investor sentiment and operational strategies.

Sol-Gel Technologies Ltd. reported first quarter 2025 financial results, with total revenue of $1 million, up from $0.5 million in Q1 2024. Research and development expenses increased to $8.8 million, primarily due to manufacturing development for SGT-610. General and administrative expenses decreased to $1.3 million. The net loss for the quarter was $8.8 million, compared to a loss of $6.3 million in the same period last year. As of March 31, 2025, the company had $16.9 million in cash and expects to fund operations into Q1 2027. Sol-Gel's pipeline includes SGT-610 and SGT-210, targeting skin diseases. The increase in revenue and R&D expenses indicates ongoing development efforts that may moderately influence financial performance.

An insider at Sol-Gel Technologies Ltd. has increased their shareholding over the past year, indicating potential confidence in the company's future performance. This move may reflect positive sentiment regarding the company's strategic direction and growth prospects. Insider buying can signal confidence in the company's future, potentially influencing market sentiment and stock performance.

Sol-Gel Technologies Ltd. announced a 10-for-1 reverse share split of its ordinary shares, effective May 2, 2025, to comply with Nasdaq's minimum bid price requirement. Shareholders approved the split at a special meeting on April 1, 2025, and the board confirmed the ratio on April 9, 2025. The adjusted par value will increase from 0.1 NIS to 1.0 NIS per share, reducing the share capital from 50 million to 5 million ordinary shares. The company's shares will continue trading under the symbol 'SLGL' with a new CUSIP number. Fractional shares will be rounded to the nearest whole share, and adjustments will be made to outstanding options and warrants. Equiniti Trust Company, LLC will act as the exchange agent. The reverse share split is a strategic move to maintain Nasdaq listing compliance, which is crucial for investor confidence and market perception.

Sol-Gel Technologies Ltd. has entered a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO, receiving $16 million in total. This agreement extends Sol-Gel's cash runway into Q1 2027, supporting its Phase III clinical trial for SGT-610, which targets a market potential of $400 to $500 million annually. The company is also progressing with its SGT-210 trial for Darier disease. Sol-Gel's CEO expressed optimism about the SGT-610 trial based on post-hoc analysis of previous studies, despite earlier results lacking statistical significance. The company aims to establish a commercial network for EPSOLAY and TWYNEO outside the U.S. The agreement with Mayne Pharma significantly enhances Sol-Gel's cash position and supports critical clinical trials, impacting future performance.

Sol-Gel Technologies Ltd. is set to report its Q4 and full-year 2024 results, with a focus on its compliance with Nasdaq requirements and pipeline developments. The Zacks Consensus Estimate anticipates revenues of $2 million and a loss of 11 cents per share. The company has seen a 46.2% decline in shares over the past year. Key products include Twyneo and Epsolay, both FDA-approved, and the pipeline candidate SGT-610, currently in phase III development. Sol-Gel received a Nasdaq notice regarding compliance, with an extension until May 2025 to meet requirements. The company has a mixed earnings surprise history, with an Earnings ESP of 0.00% and a Zacks Rank of #3. The upcoming earnings report and compliance updates may moderately influence financial performance and investor sentiment.

Sol-Gel Technologies (NASDAQ:SLGL) has $28 million in cash and a cash burn of $17 million, providing a cash runway of approximately 20 months. Despite a 16% increase in cash burn year-on-year, the company reported an impressive 870% growth in operating revenue. However, its cash burn represents about 80% of its market capitalization of $21 million, raising concerns about potential funding difficulties. While revenue growth is promising, the high cash burn relative to market cap poses risks for shareholders. The significant cash burn relative to market cap could moderately influence financial performance and investor sentiment.

SolGel Technologies (SLGL) is highlighted as a strong value stock, currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. Its P/B ratio of 1.32 is significantly lower than the industry average of 3.77, indicating potential undervaluation. Additionally, SLGL's P/S ratio of 2.33 is also below the industry's average of 2.78. These metrics suggest that SLGL is likely undervalued, supported by a positive earnings outlook. Strong valuation metrics and a positive earnings outlook indicate significant potential for future performance.

Sol-Gel Technologies Ltd. (SLGL) beats expectations in third quarter 2024 earnings. The article reports on significant impact likely on future performance due to beating expectations in earnings.

Sol-Gel Technologies Ltd. reports Q3 2024 financial results, appoints Mori Arkin as interim CEO, ongoing Phase 3 trials for SGT-610 and SGT-210, signs new agreements, and expects positive revenue streams from TWYNEO and EPSOLAY. The article discusses significant corporate developments, ongoing clinical trials, new agreements, and potential revenue streams that could have a substantial impact on Sol-Gel's future performance.

Sol-Gel Technologies Ltd. (SLGL) upgraded to Zacks Rank #1 (Strong Buy) due to rising earnings estimates, indicating positive outlook for stock price. The article highlights significant impact on Sol-Gel Technologies' future and market performance through improved earnings outlook and potential stock price increase.

Sol-Gel Technologies reported strong second quarter 2024 earnings, with revenue and net income exceeding expectations. The earnings beat and forecasted revenue growth of 52% p.a. indicate a significant impact on the company's future performance.

Sol-Gel Technologies Ltd. reports financial results for Q2 2024, extends cash runway, ongoing clinical trials for SGT-610 and SGT-210, signs license agreements for TWYNEO and EPSOLAY, management realignment, and appoints interim CEO. The article discusses significant financial results, ongoing clinical trials, strategic agreements, and management changes that could have a profound impact on Sol-Gel's future trajectory.

Sol-Gel Technologies Ltd. (SLGL) beat Q2 earnings and revenue estimates by a significant margin, with adjusted earnings of $0.07 per share and revenues of $5.43 million. The article indicates a significant impact on Sol-Gel Technologies Ltd.'s future performance and market sentiment due to the earnings beat and revenue surpassing estimates.